Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/112843
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Biomedical Engineering-
dc.creatorWang, J-
dc.creatorZhao, Z-
dc.creatorWang, Q-
dc.creatorShi, J-
dc.creatorWong, DWC-
dc.creatorCheung, JCW-
dc.date.accessioned2025-05-09T06:12:38Z-
dc.date.available2025-05-09T06:12:38Z-
dc.identifier.urihttp://hdl.handle.net/10397/112843-
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.rightsCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_US
dc.rightsThe following publication Wang, J., Zhao, Z., Wang, Q., Shi, J., Wong, D. W.-C., & Cheung, J. C.-W. (2024). Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review. Vaccines, 12(12), 1335 is available at https://doi.org/10.3390/vaccines12121335.en_US
dc.subjectAdjuvantsen_US
dc.subjectNanoparticlesen_US
dc.subjectTuberculosisen_US
dc.subjectVaccinesen_US
dc.titleAdvancements in nanoparticle-based adjuvants for enhanced tuberculosis vaccination : a reviewen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume12-
dc.identifier.issue12-
dc.identifier.doi10.3390/vaccines12121335-
dcterms.abstractTuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, necessitating the development of more effective vaccines. Nanoparticle-based adjuvants represent a promising approach to enhancing tuberculosis vaccine efficacy. This review focuses on the advantages of nanoparticulate-loaded vaccines, emphasizing their ability to improve antigen delivery, safety, and immunogenicity. We discuss the various types of nanoparticles and their unique physicochemical properties that contribute to improved antigen delivery and sustained immune activation. Additionally, we highlight the advantages of nanoparticle-based adjuvants in inducing strong cellular and humoral immunity, enhancing vaccine stability, and reducing adverse effects. Finally, we address current challenges and future perspectives in the application of these novel adjuvants, emphasizing their potential to transform TB vaccine strategies and ultimately contribute to better global health outcomes.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationVaccines, Dec. 2024, v. 12, no. 12, 1335-
dcterms.isPartOfVaccines-
dcterms.issued2024-12-
dc.identifier.scopus2-s2.0-85213081715-
dc.identifier.eissn2076-393X-
dc.identifier.artn1335-
dc.description.validate202505 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceSelf-fundeden_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
vaccines-12-01335-v2.pdf4.08 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

SCOPUSTM   
Citations

5
Citations as of Dec 19, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.